Stockscreener 앱 받기
38.26
1.95%
0.73
시간 외 거래:
38.28
0.02
+0.05%
전일 마감가:
$37.53
열려 있는:
$37.57
하루 거래량:
14.01M
Relative Volume:
1.15
시가총액:
$168.94B
수익:
$50.91B
순이익/손실:
$18.95B
주가수익비율:
8.9791
EPS:
4.261
순현금흐름:
$1.92B
1주 성능:
+0.92%
1개월 성능:
-17.90%
6개월 성능:
+3.66%
1년 성능:
-35.17%
1일 변동 폭
$37.51
$38.47
1주일 범위
$36.84
$38.47
52주 변동 폭
$35.12
$64.16
노보 노디스크 Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
38.26 | 164.79B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,188.72 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.45 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
271.36 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
142.79 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.28 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2026-03-18 | 개시 | Bernstein | Outperform |
| 2026-03-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-03-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2026-02-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Kepler | Buy → Hold |
| 2026-02-23 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2026-02-12 | 업그레이드 | Jefferies | Underperform → Hold |
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2025-12-08 | 다운그레이드 | Argus | Buy → Hold |
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
Eli Lilly vs. Novo Nordisk: valuation gap and pairs trade framework - Investing.com
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections - Zacks Investment Research
Novo Nordisk A/S Sponsored ADR Class B Earnings and Revenue – HAN:NOVA - TradingView
NOVA Forecast — Price Target — Prediction for 2027 - TradingView
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk Weighs Direct NYSE Listing as U.S. Investors Push for Closer Access - finance.biggo.com
Novo Nordisk Is Open To A Direct NYSE Listing - Finimize
Novo Nordisk CEO opens the door to major move for U.S. investors - thestreet.com
Novo Nordisk open to direct NYSE listing, CEO s... - Pluang
Novo CEO Considering Direct Shares Listing: Report - Pharmaceutical Executive
Novo Nordisk Open to Direct NYSE Listing, CEO Tells FT - Global Banking & Finance Review
Key facts: NOVO_B: DKK150bn Plan; Mixed CagriSema, Oral Wegovy Sales - tradingview.com
Novo wants to change how Wall Street owns its stock: why now - Invezz
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT By Reuters - Investing.com
Novo Nordisk stock falls sharply as Capital Markets Day disappoints investors - AD HOC NEWS
Novo's Cardiometabolic Business Is Concentrated in Semaglutide, but the Pipeline Is Growing - Morningstar
European ADRs Started The Week Higher In US Trading - Finimize
Novo Nordisk Stock Slides 8% as $23 Billion Pipeline Goal Leaves a 2032 Gap - TechStock²
Novo Nordisk ADR shares tumble over 7% on Wall Street as long-term plan fails to impress investors - upstox.com
Novo-Nordisk stock heads into the open after a 0.1 percent gain - AD HOC NEWS
Novo Nordisk stock reacts to CHMP backing for FREHEMGO and Novo rebranding - AD HOC NEWS
Novo Nordisk stock gains as analysts see up to 50 percent upside - AD HOC NEWS
Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A - Finansavisen
Novo Nordisk stock heads into the open after a 2.1% slide - AD HOC NEWS
Novo Nordisk stock falls as rebrand to Novo meets cautious analyst response - AD HOC NEWS
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk stock extends buyback as trial updates and obesity growth shape outlook - ad-hoc-news.de
Novo Nordisk (NYSE: NVO) has bought back 32M shares, with its 12‑month repurchase plan still running - Stock Titan
Novo Nordisk stock heads into the open after a 2.3% slide - AD HOC NEWS
Novo Nordisk stock falls as heart drug trials are halted despite pediatric obesity win - AD HOC NEWS
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Novo Nordisk trial shows semaglutide helped 40% of children - Investing.com
Weekly Recap: Oral Wegovy launch in Germany and DKK8.7077bn buyback - TradingView
Novo Nordisk stock dips as Wegovy pill launch in Germany reshapes obesity market - AD HOC NEWS
European ADRs Push Higher In Wednesday Session Led By ING, IHG, And Novo Nordisk - foreignpolicyjournal.com
From hunger to obesity: Developing world faces growing threat to child health By Reuters - Investing.com
European ADRs Inched Higher As Healthcare Led Gains - Finimize
Novo Nordisk stock reacts to downgrade as oral obesity push advances in Asia - ad-hoc-news.de
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):